Another study [10], revealed similar results showing that elevated baseline levels of cTnI (>40 ng/L) in 13.6% (56 of 412) and cTnT (>14 ng/L) in 24.8% of (101 of 407) HER2+ breast cancer patients were associated with a significantly higher risk of LVEF decline (hazard ratio (HR) of 4.52, 95% CI (2.45–8.35), p < 0.001 and 3.57; 95% CI (1.95–6.55), p < 0.001 in the univariate model, respectively) in response to trastuzumab treatment. The gene discussed is TNNT2; the disease is breast carcinoma.